Impaired social interaction · children aged 5 to 11 years with ASD
1 finding from 1 review
Social communication impairment · children aged 5 to 11 years with ASD
1 finding from 1 review
Stereotyped patterns of behaviour and interests · children aged 5 to 11 years with ASD
1 finding from 1 review
Total adverse events · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐core symptoms of ASD · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in non‐core symptoms of ASD compared with placebo (low certainty).
1 finding from 1 review
Tolerability · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in tolerability compared with placebo (low certainty).
1 finding from 1 review
ADHD symptoms – improvement – medium term · Children and adolescents with ADHD
Summary of findings table ‐ PUFA may leads to higher ADHD symptoms – improvement – medium term compared with placebo (low certainty).
1 finding from 1 review
ADHD symptoms · Children and adolescents with ADHD
1 finding from 1 review
ADHD symptoms – inattention, parent‐rated – medium term · Children and adolescents with ADHD
1 finding from 1 review
ADHD symptoms – hyperactivity/impulsivity, parent‐rated – medium term · Children and adolescents with ADHD
1 finding from 1 review
Side effects – overall · Children and adolescents with ADHD
Summary of findings table ‐ PUFA showed no clear difference in side effects – overall compared with placebo (moderate certainty).
1 finding from 1 review
Loss to · Children and adolescents with ADHD
Summary of findings table ‐ PUFA showed no clear difference in loss to compared with placebo (moderate certainty).
1 finding from 1 review
ADHD symptoms · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes ADHD symptoms: all parallel‐group trials and first‐period cross‐over… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse events · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes proportion of participants with one or more serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious (penicillin versus doxycycline) · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes proportion of participants with one or more adverse events… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
General behaviour: all parallel‐group trials and first‐period cross‐over trials General behaviour rating scales (Teacher‐rated) · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes general behaviour: all parallel‐group trials and first‐period… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
QoL · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes quality of life (parent‐rated) compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Irritability · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐injury · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review